% | $
Quotes you view appear here for quick access.

Optimer Pharmaceuticals, AŞ Message Board

  • akos103 akos103 Dec 1, 2011 6:41 PM Flag

    Jefferies update on OPTR today

    Jefferies maintains its Buy rating and $17 price target on Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) as it believes current valuation is attractive.

    Jefferies notes, “At its Investor and Analyst Reception on Dec 5, we expect OPTR to highlight Dificid's potential in high-risk CDAD population, its value proposition to payers, and insight into 4Q11 sales. Despite recent volatility in share price due to potential financing overhang, increased SG&A, and fluctuating IMS data, at EV of ~$370M, we believe the Street's cautious expectations for Dificid pose significant upside for OPTR shares.”

    OPTR closed at $10.74 per share on Wednesday.

    SortNewest  |  Oldest  |  Most Replied Expand all replies